Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited announced that Xinxin Pharmaceutical Plant has recently received a Drug Registration Certificate issued by the National Medical Products Administration of the People's Republic of China (Guo Jia Yao Pin Jian Du Guan Li Ju) in respect of Loxoprofen Sodium Cataplasms (Luo Suo Luo Fen Na Ning Xiao Tie Gao). The key details of the Drug Registration Certificate and the other relevant information on the Drug are set out in Appendix A to this announcement. The Company places great emphasis on pharmaceutical research and development ("R&D") and exercises strict quality and safety controls across the entire chain of drug R&D, manufacturing, and distribution.
The Drug was submitted for registration as a Category 4 chemical drug. Upon approval, the Drug is deemed to have passed the quality and efficacy consistency evaluation with the reference-listed drug. The approval for registration of the Drug, which signifies that it meets the relevant requirements for drug registration, is not expected to have a material impact on the Company's short-term financial performance.
There may be uncertainties during the period from marketing approval to actual production and sales of the Drug. Factors such as national policies and market conditions may affect the scale of future production and sales of the Drug". Shareholders and potential investors are advised to exercise caution when trading in the shares of the Company.
By Order of the Board. Jiao Yan. Secretary to the Board of Directors.
25 November 2025.
